ALPHAMAB-B (09966) rose more than 6%, and as of the time of writing, it was up 6.76% to HK$10.89, with a turnover of HK$10.4175 million. Recently, ALPHAMAB-B announced that the Investigational New Drug (IND) application for a Phase II clinical trial of JSKN033—a high-concentration subcutaneous compound preparation composed of an anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody-drug conjugate (ADC) combined with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor—in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer has been formally accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. JSKN033-202 is an open-label, multicenter, Phase II clinical trial designed to evaluate the safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics of JSKN033 combined with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for patients with advanced cervical cancer. All patients will receive treatment with JSKN033 combined with cisplatin or carboplatin, with or without bevacizumab. The choice of platinum-based drug and the decision on whether to use bevacizumab will be determined by the investigator based on the specific circumstances of each patient.